Response and toxicity prediction by MALDI-TOF-MS serum peptide profiling in patients with non-small cell lung cancer
| Autor: | Egbert F. Smit, Joline S.W. Lind, Thang V. Pham, Henk M.W. Verheul, Jaco C. Knol, Johannes Voortman, Connie R. Jimenez, Maria Rovithi |
|---|---|
| Přispěvatelé: | Medical oncology, CCA - Biomarkers, Pulmonary medicine, Medical oncology laboratory |
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
Niacinamide
Proteomics 0301 basic medicine Sorafenib Oncology medicine.medical_specialty Lung Neoplasms Clinical Biochemistry Peptide Disease-Free Survival Proto-Oncogene Proteins p21(ras) Erlotinib Hydrochloride 03 medical and health sciences 0302 clinical medicine Carcinoma Non-Small-Cell Lung Internal medicine Antineoplastic Combined Chemotherapy Protocols Biomarkers Tumor medicine Humans Clinical significance Lung cancer chemistry.chemical_classification business.industry Phenylurea Compounds medicine.disease ErbB Receptors Treatment Outcome 030104 developmental biology chemistry Spectrometry Mass Matrix-Assisted Laser Desorption-Ionization 030220 oncology & carcinogenesis Mutation Cohort Toxicity Erlotinib Peptides business medicine.drug |
| Zdroj: | Rovithi, M, Lind, J S W, Pham, T V, Voortman, J, Knol, J C, Verheul, H M W, Smit, E F & Jimenez, C R 2016, ' Response and toxicity prediction by MALDI-TOF-MS serum peptide profiling in patients with non-small cell lung cancer ', Proteomics. Clinical applications, vol. 10, no. 7, pp. 743-749 . https://doi.org/10.1002/prca.201600025 Proteomics. Clinical applications, 10(7), 743-749. Wiley-VCH Verlag |
| ISSN: | 1862-8346 |
| Popis: | Purpose We validated a previously reported proteomic signature, associated with treatment outcome, in an independent cohort of patients with non-small cell lung cancer (NSCLC). A novel peptide signature was developed to predict toxicity. Experimental design Using automated magnetic C18 bead-assisted serum peptide capture coupled to MALDI-TOF MS, we conducted serum peptide profiling of 50 NCSLC patients participating in a phase II trial of erlotinib and sorafenib. On the obtained peptide mass profiles, we applied a previously described proteomic classification algorithm. Additionally, associations between observed side effects and peptide profiles were investigated. Results Application of the previously acquired algorithm successfully classified the new cohort of patients in groups significantly associated with the outcome. The "poor" group exhibited shorter median progression-free survival (PFS) and overall survival (OS) of 1.35 and 1.98 months (with p = 0.00677 and p = 0.00002, respectively) while the "good" group had significantly longer PFS and OS (10.63 and 14.4 months with p = 0.00142 and p = 0.00002, respectively), compared to average OS and PFS. Two specific peptides were detected in the sera of all patients that developed severe toxicity. Conclusions and clinical relevance Our results provide an algorithm that, following prospective validation in larger cohorts, could assist treatment selection of patients with NSCLC in the first line setting. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text